申请人:Gurley David
公开号:US20050245595A1
公开(公告)日:2005-11-03
Compounds according to formula I:
wherein R
1
, W, R
2
, R
3
, X, R
4
and R
5
are as described in the specification, enantiomers thereof, pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission.
按照公式I的化合物:其中R1、W、R2、R3、X、R4和R5如规范所述,其对映异构体,其药物学上可接受的盐,制备它们的过程,含有它们的制药组合物以及它们在治疗中的应用,特别是用于治疗与尼古丁传递减少相关的疾病。